Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06267274 · ClinicalTrials.gov registry record · Phase 1
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
A Phase 1 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Amneal Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 240
- Enrollment target
- 4
- Study locations
NCT06267274 is a Phase 1 study of Ocular Hypertension and Open Angle Glaucoma that is actively recruiting participants, run by Amneal Pharmaceuticals. The registered enrollment target is 240 participants, below the 274-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (12% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT06267274, a Phase 1 study of Ocular Hypertension and Open Angle Glaucoma, is actively recruiting participants, sponsored by Amneal Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 240 participants
- Enrollment target
- 4
- Study locations
Study Summary
A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study
Conditions Studied
Interventions
- DRUG Bimatoprost Ophthalmic Solution, 0.01%
- DRUG LUMIGAN® (bimatoprost ophthalmic solution) 0.01%
Study Locations (4)
California
- West Coast Eye Institute - Bakersfield
- Eye Research Foundation - Newport Beach
Georgia
- Clayton Eye Research - Morrow
Texas
- Houston Eye Associates - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2025-05-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06267274
The ClinicalTrials.gov registry entry for NCT06267274 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 274-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (12% lower). The listed sponsor is Amneal Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Bimatoprost Ophthalmic Solution, 0.01% is the first listed.
NCT06267274 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Georgia, Texas.
Frequently Asked Questions
What is clinical trial NCT06267274 about?
NCT06267274 is a clinical study titled "A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes". A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study
What is the current status of trial NCT06267274?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2024-04-01. Estimated completion is 2025-05-01.
What conditions does trial NCT06267274 study?
This clinical trial studies the following conditions: Ocular Hypertension, Open Angle Glaucoma.
What interventions are being tested in trial NCT06267274?
The interventions under investigation include: Bimatoprost Ophthalmic Solution, 0.01% (DRUG), LUMIGAN® (bimatoprost ophthalmic solution) 0.01% (DRUG).
Who is sponsoring clinical trial NCT06267274?
This trial is sponsored by Amneal Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06267274 being conducted?
This trial has 4 study locations across California, Georgia, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 1
-
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
ACTIVE NOT RECRUITING · Phase 1
-
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
ACTIVE NOT RECRUITING · Phase 1
-
Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma
COMPLETED · Phase 1
-
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
COMPLETED · Phase 1
-
Safety and IOP-Lowering Effects of WB007
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.